Skip to main content

Table 5 Summary of the most frequently reported adverse events a

From: Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study

 

GSK933776 dose

Adverse events

1 mg/kg ( N/n = 6/6)

3 mg/kg ( N/n = 6/6)

6 mg/kg ( N/n = 6/6)

Any event

3 (50)

5 (83)

5 (83)

Fatigue

0

2 (33)

2 (33)

Headache

1 (17)

4 (67)

2 (33)

Nausea

0

3 (50)

1 (17)

Vomiting

0

2 (33)

1 (17)

Back pain

1 (17)

2 (33)

1 (17)

Nasopharyngitis

0

0

0

Neck pain

0

1 (17)

1 (17)

Atrial fibrillation

1 (17)

0

1 (17)

Procedural headache

0

1 (17)

1 (17)

  1. aData in parentheses are percentages.